Is Marijuana “Legal” Now? The Cannabis Industry and Your Risk

by Williams Mullen

Williams Mullen

As more states join the majority, regulating some form of medical or recreational marijuana, the federal government’s position remains unchanged.  Under federal law, it remains illegal to cultivate, process, distribute or possess marijuana.  This has placed entrepreneurs, investors and service providers in a quandary.  This alert provides a legal analysis and a risk assessment for participants in a new, evolving and uncharted industry.

Federal Regulation of Marijuana

All drugs must be approved by the Food and Drug Administration (FDA) if they are sold legally in the United States.  The FDA will only approve a drug after the FDA's Center for Drug Evaluation and Research (CDER) determines that it provides benefits that outweigh its known and potential risks for the intended population.  Certain drugs are further deemed “controlled substances” and regulated by the Drug Enforcement Administration (DEA) pursuant to the Controlled Substances Act of 1970 (CSA).  The CSA divides controlled substance into five “schedules” based on the drug’s abuse potential, medical applications, and safety.

Marijuana, cannabinoids and their analogues, in whatever form and by whatever name, are Schedule I drugs, like heroin, LSD or Psilocybin, due to their high potential for abuse, lack of any currently accepted medical use in treatment in the United States, and lack of accepted safety for use of the drug or other substance under medical supervision.  (21 U.S.C. § 812(b)(1)).  Medical marijuana cannot be legal, under federal law, unless and until the FDA reclassifies it as a Schedule II drug, something the current administration is unlikely to pursue after considering the factors listed in Section 201 (c), [21 U.S.C. § 811 (c)] of the CSA:

  1. Its actual or relative potential for abuse.
  2. Scientific evidence of its pharmacological effect, if known.
  3. The state of current scientific knowledge regarding the drug or other substance.
  4. Its history and current pattern of abuse.
  5. The scope, duration, and significance of abuse.
  6. What, if any, risk there is to the public health.
  7. Its psychic or physiological dependence liability.
  8. Whether the substance is an immediate precursor of a substance already controlled under this subchapter.

Manufacturing and distributing marijuana remain illegal under federal law, and it is punishable by up to life imprisonment to “knowingly or intentionally. . . manufacture, distribute, or dispense, or possess with intent to manufacture, distribute or dispense, a controlled substance.”  (21 U.S.C. § 841(a)).  Even a licensed doctor or pharmacist may not legally prescribe marijuana as it does not have the legitimate medical purpose required by 21 C.F.R. § 1306.04. 

Federal statutes also make it illegal to conspire to traffic drugs (21 U.S.C. § 846) or to aid and abet an offense against the United States (18 U.S.C. § 2).  Further, it is unlawful to knowingly conduct or attempt to conduct a financial transaction that in fact involves the proceeds of specified unlawful activity or with the intent to promote the carrying on of specified unlawful activity (18 U.S. Code §§ 1956 and 1957).  These charges are commonly referred to as “money laundering” and often are used interchangeably, though § 1957 removes the intent requirement and adds a requirement that the transaction be for greater than $10,000.

State Law Trends

The clear political trend is that states are moving toward some form of legalized medical marijuana and a smaller number have decriminalized possession of small amounts for personal use.  Per the National Council of State Legislatures, Alaska, California, Colorado, Maine, Massachusetts, Nevada, Oregon, Washington and the District of Columbia have legalized small amounts of marijuana for adult use.  As of Jan. 22, 2018, the Vermont legislature passed adult-use legalization legislation, and the governor signed the bill.  The measure does not set up a regulatory system for sales or production.

Some 28 states, the District of Columbia, Guam and Puerto Rico have comprehensive medical marijuana programs, and at least another 17 states allow the use of products with low-THC (the active ingredient in marijuana) for medical purposes.

Most political observers believe that additional states will legalize medical marijuana in the coming years and that the revenue recognized by businesses, and the resultant tax receipts, will incentivize legislators looking to close budget gaps, specifically states like Virginia that are likely to expand Medicaid under the Affordable Care Act soon.

Federal Enforcement Under Presidents Obama and Trump

On August 29, 2013 Deputy Attorney General Cole issued a policy memorandum on behalf of the Obama Administration.  (Memorandum from James M. Cole, Deputy Attorney General, United States Department of Justice, to United States Attorneys, Guidance Regarding Marijuana Enforcement, see here).  Contrary to the wishful thinking of some at the time, the Cole Memorandum did not provide “immunity” or otherwise insulate individuals or corporations from prosecution.  The policy simply stated that federal prosecutors should not charge cases against businesses that are complying with state laws.  Notably, Cole did not address civil monetary penalties, regulatory action or civil forfeiture.  Civil forfeiture allows the federal government to seize any assets involved in or traceable to a marijuana business.  (18 U.S.C. §§ 981, 983)

In January 2018, Attorney General Jeff Sessions, citing a “return to the rule of law,” issued a Department of Justice (DOJ) Memorandum For All United States Attorneys in which he stated that “previous nationwide guidance specific to marijuana enforcement is unnecessary and is rescinded," see here.  This was an explicit repudiation of the Cole guidance and signaled Sessions’ long-standing policy regarding any form of legalized marijuana.

Though several United States Senators, Governors and Attorneys General in states with medical or recreational marijuana laws objected, the potential for federal prosecutions of marijuana possession, manufacturing and distribution remains.  Several current United States Attorneys, including those in states like California, Colorado, Oregon, Vermont and Washington, and in the District of Columbia, have issued statements expressing tepid support for the Sessions Memo while noting that each will continue to focus on “hard drugs” per Maine’s United States Attorney, Halsey B. Frank.  Bob Troyer, U.S. Attorney for the District of Colorado, the first state to have legal, regulated sales of recreational marijuana, issued the following statement:

“Today the Attorney General rescinded the Cole Memo on marijuana prosecutions, and directed that federal marijuana prosecution decisions be governed by the same principles that have long governed all of our prosecution decisions.  The United States Attorney’s Office in Colorado has already been guided by these principles in marijuana prosecutions — focusing in particular on identifying and prosecuting those who create the greatest safety threats to our communities around the state.  We will, consistent with the Attorney General’s latest guidance, continue to take this approach in all of our work with our law enforcement partners throughout Colorado.”

Washington, DC is a jurisdiction with a growing “gift economy” whereby vendors sell overpriced consumer goods and include “free” or “souvenir” marijuana, exploiting an alleged grey area in the District’s laws.  Jesse K. Liu, the United States Attorney for the District of Columbia, said in a statement:

“The U.S. Attorney’s Office for the District of Columbia is committed to reducing violent crime and dismantling criminal gangs and large-scale drug distribution networks that pose a threat to public safety.  In accordance with the Attorney General’s memo, we will utilize long-established principles of prosecutorial discretion in pursuing cases and fulfilling that commitment.”

These statements, from federal prosecutors appointed by President Trump, are representative of those from other prosecutors.  These statements provide individuals and companies engaged in marijuana cultivation and sale with cold comfort.  Each prosecutor seemingly acknowledges that federal marijuana prosecutions are not public safety priorities, without declining to bring marijuana cases in the future, particularly where accompanied by violent crime, organized crime or other aggravating factors.

Support and Ancillary Services and Products

Lawyers, financial institutions, landlords, vendors, payment processors, investors and others may not be directly involved in cultivating or distributing marijuana, but may be prosecuted as co-conspirators, aiders or abettors or under 21 USC § 856, which makes it a separate crime to “manage or control any place. . . for the purpose of unlawfully manufacturing, storing, distributing, or using a controlled substance.”  One of the authors of this memorandum has personally prosecuted large scale “grow houses” in the Eastern District of Virginia pursuant to this statute.

Industry observers and participants are rightly concerned that the Department of Justice may choose to forgo a criminal prosecution in favor of a civil action against a marijuana industry participant, even without a criminal charge.  Given the hundreds, if not thousands, of potential defendants, it is most likely that any such action would be initiated against an individual or entity with prior convictions, accompanying impact on public safety or some other aggravating factor. 

A review of news articles, federal prosecutions, industry trade publications and other research does not reveal an uptick in federal prosecutions of those involved in medical or recreational marijuana, whether in a state where “legal” or not.  Given the limited investigative and prosecutorial resources available, the finances involved and the political climate, a prosecution of a support or ancillary service provider is unlikely now.  Should the Department of Justice charge a participant in a state that has some form of legalized marijuana, it would be in an exceptional case.  Recognizing that federal law is not affected by states’ actions regarding medical or recreational marijuana, the exposure for a market participant that operates within the confines of the laws and regulations of the state or states in which it operates are greatly reduced.  But, exposure for violations of federal law is not eliminated.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Williams Mullen | Attorney Advertising

Written by:

Williams Mullen

Williams Mullen on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.